| Literature DB >> 32937153 |
Nandini Acharya1, Asaf Madi2, Huiyuan Zhang1, Max Klapholz1, Giulia Escobar1, Shai Dulberg3, Elena Christian4, Michelle Ferreira5, Karen O Dixon1, Geoffrey Fell6, Katherine Tooley1, Davide Mangani1, Junrong Xia1, Meromit Singer7, Marcus Bosenberg5, Donna Neuberg6, Orit Rozenblatt-Rosen8, Aviv Regev9, Vijay K Kuchroo10, Ana C Anderson11.
Abstract
Identifying signals in the tumor microenvironment (TME) that shape CD8+ T cell phenotype can inform novel therapeutic approaches for cancer. Here, we identified a gradient of increasing glucocorticoid receptor (GR) expression and signaling from naïve to dysfunctional CD8+ tumor-infiltrating lymphocytes (TILs). Conditional deletion of the GR in CD8+ TILs improved effector differentiation, reduced expression of the transcription factor TCF-1, and inhibited the dysfunctional phenotype, culminating in tumor growth inhibition. GR signaling transactivated the expression of multiple checkpoint receptors and promoted the induction of dysfunction-associated genes upon T cell activation. In the TME, monocyte-macrophage lineage cells produced glucocorticoids and genetic ablation of steroidogenesis in these cells as well as localized pharmacologic inhibition of glucocorticoid biosynthesis improved tumor growth control. Active glucocorticoid signaling associated with failure to respond to checkpoint blockade in both preclinical models and melanoma patients. Thus, endogenous steroid hormone signaling in CD8+ TILs promotes dysfunction, with important implications for cancer immunotherapy.Entities:
Keywords: CD8(+) T cell; Nr3c1; TCF-1; cancer; dysfunction; exhaustion; glucocorticoid; immune checkpoint blockade; steroid; tumor-associated macrophages
Mesh:
Substances:
Year: 2020 PMID: 32937153 PMCID: PMC7682805 DOI: 10.1016/j.immuni.2020.08.005
Source DB: PubMed Journal: Immunity ISSN: 1074-7613 Impact factor: 31.745